Therapeutic Solutions International Inc (TSOI)

[centsability4me]

DISCUSSION

We have established that pterostilbene can potentiate the anticancer effects in GCs of two drugs, the EGFR inhibitor gefitinib and the SSRI sertraline. Pterostilbene is regarded as a nontoxic compound and has good brain bioavailability [9–13]. Both EGFR inhibition and repurposing of sertraline have been proposed for GBM therapy, the latter as a component of a 9-drug combination protocol [23]. Our results warrant consideration of pterostilbene to be added to combinatorial treatment approaches involving sertraline. The association of PG to EGFR mutation and the CL subtype (which is characterized by EGFR amplification [25, 37]) are logical given that gefitinib targets EGFR, and we suggest pterostilbene potentiates the effect of gefitinib in a subset of Classical GBM. The findings suggest that pterostilbene may be a relevant potentiator of EGFR-inhibitors with good CNS penetration now under development.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341973/

Pterostilbene has been clinically evaluated for safety in human subjects [49], but remains to be systematically assessed as an anticancer agent in humans. It is also important to consider possible side effects of antioxidants, including stilbenoids, on tumor progression. For instance, experimental mice fed antioxidants have been reported to carry an increased tumor burden and increased rates of metastasis [50, 51]. A similar effect in glioma has not been reported, however one study indicates no consistent or significant association between antioxidant consumption and overall survival in glioblastoma patients [52]. Future work will be needed to evaluate the promise of pterostilbene-induced drug synergism in vivo.

(As the research goes deeper into these areas , the edge moves forward - IMHO )